
1. j trop med hyg. 2014 oct;91(4):833-843. doi: 10.4269/ajtmh.14-0031. epub 2014 
jul 21.

polymorphisms plasmodium falciparum chloroquine resistance transporter and
multidrug resistance 1 genes: parasite risk factors affect treatment
outcomes p. falciparum malaria artemether-lumefantrine and
artesunate-amodiaquine.

venkatesan m, gadalla nb, stepniewska k, dahal p, nsanzabana c, moriera c, price 
rn, mårtensson a, rosenthal pj, dorsey g, sutherland cj, guérin p, davis tme,
ménard d, adam i, ademowo g, arze c, baliraine fn, berens-riha n, björkman a,
borrmann s, checchi f, desai m, dhorda m, djimdé aa, el-sayed bb, eshetu t, eyase
f, falade c, faucher jf, fröberg g, grivoyannis a, hamour s, houzé s, johnson j, 
kamugisha e, kariuki s, kiechel jr, kironde f, kofoed pe, lebras j, malmberg m,
mwai l, ngasala b, nosten f, nsobya sl, nzila a, oguike m, otienoburu sd, ogutu
b, ouédraogo jb, piola p, rombo l, schramm b, somé af, thwing j, ursing j, wong
rpm, zeynudin a, zongo i, plowe cv, sibley ch, asaq molecular marker study group.

erratum in
    j trop med hyg. 2015 may;92(5):1084.
    j trop med hyg. 2019 mar;100(3):766.

adequate clinical parasitologic cure artemisinin combination therapies
relies artemisinin component partner drug. polymorphisms the
plasmodium falciparum chloroquine resistance transporter (pfcrt) p.
falciparum multidrug resistance 1 (pfmdr1) genes associated decreased
sensitivity amodiaquine lumefantrine, effects polymorphisms
on therapeutic responses artesunate-amodiaquine (asaq) and
artemether-lumefantrine (al) clearly defined. individual patient
data 31 clinical trials harmonized pooled using standardized
methods worldwide antimalarial resistance network. data than
7,000 patients analyzed assess relationships parasite
polymorphisms pfcrt pfmdr1 clinically relevant outcomes after
treatment al asaq. presence pfmdr1 gene n86 (adjusted hazards
ratio = 4.74, 95% confidence interval = 2.29 - 9.78, p < 0.001) increased
pfmdr1 copy number (adjusted hazards ratio = 6.52, 95% confidence interval =
2.36-17.97, p < 0.001 : significant independent risk factors for
recrudescence patients treated al. al asaq exerted opposing selective
effects single-nucleotide polymorphisms pfcrt pfmdr1. monitoring
selection responding emerging signs drug resistance critical tools 
for preserving efficacy artemisinin combination therapies; determination of
the prevalence least pfcrt k76t pfmdr1 n86y routine.

© american society tropical medicine hygiene.

doi: 10.4269/ajtmh.14-0031 
pmcid: pmc4183414
pmid: 25048375  [indexed medline]

